Pulmonx LUNG Stock
Pulmonx Price Chart
Pulmonx LUNG Financial and Trading Overview
| Pulmonx stock price | 1.52 USD |
| Previous Close | 1.65 USD |
| Open | 1.54 USD |
| Bid | 1.24 USD x 200 |
| Ask | 2.03 USD x 200 |
| Day's Range | 1.54 - 1.72 USD |
| 52 Week Range | 1.13 - 3.88 USD |
| Volume | 551.48K USD |
| Avg. Volume | 553.84K USD |
| Market Cap | 67.16M USD |
| Beta (5Y Monthly) | 0.179 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.4 USD |
LUNG Valuation Measures
| Enterprise Value | 61.88M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.5229884 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.75845224 |
| Price/Book (mrq) | 1.4681442 |
| Enterprise Value/Revenue | 0.699 |
| Enterprise Value/EBITDA | -1.21 |
Trading Information
Pulmonx Stock Price History
| Beta (5Y Monthly) | 0.179 |
| 52-Week Change | -50.00000000000000000000000000000000% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 3.88 USD |
| 52 Week Low | 1.13 USD |
| 50-Day Moving Average | 1.36 USD |
| 200-Day Moving Average | 1.67 USD |
LUNG Share Statistics
| Avg. Volume (3 month) | 553.84K USD |
| Avg. Daily Volume (10-Days) | 433.42K USD |
| Shares Outstanding | 42.24M |
| Float | 37.27M |
| Short Ratio | 5.13 |
| % Held by Insiders | 4.66% |
| % Held by Institutions | 79.14% |
| Shares Short | 2.7M |
| Short % of Float | 7.58% |
| Short % of Shares Outstanding | 6.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -60.092% |
| Operating Margin (ttm) | -62.93% |
| Gross Margin | 75.48% |
| EBITDA Margin | -57.77% |
Management Effectiveness
| Return on Assets (ttm) | -24.038% |
| Return on Equity (ttm) | -86.21% |
Income Statement
| Revenue (ttm) | 88.55M USD |
| Revenue Per Share (ttm) | 2.15 USD |
| Quarterly Revenue Growth (yoy) | -8.69% |
| Gross Profit (ttm) | 66.84M USD |
| EBITDA | -51160000 USD |
| Net Income Avi to Common (ttm) | -53209000 USD |
| Diluted EPS (ttm) | -1.3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 61.57M USD |
| Total Cash Per Share (mrq) | 1.46 USD |
| Total Debt (mrq) | 56.29M USD |
| Total Debt/Equity (mrq) | 123.02 USD |
| Current Ratio (mrq) | 4.906 |
| Book Value Per Share (mrq) | 1.083 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -29251000 USD |
| Levered Free Cash Flow (ttm) | -8362750 USD |
Profile of Pulmonx
| Country | United States |
| State | CA |
| City | Redwood City |
| Address | 700 Chesapeake Drive |
| ZIP | 94063 |
| Phone | 650 364 0400 |
| Website | https://pulmonx.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 296 |
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Q&A For Pulmonx Stock
What is a current LUNG stock price?
Pulmonx LUNG stock price today per share is 1.52 USD.
How to purchase Pulmonx stock?
You can buy LUNG shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pulmonx?
The stock symbol or ticker of Pulmonx is LUNG.
Which industry does the Pulmonx company belong to?
The Pulmonx industry is Medical Devices.
How many shares does Pulmonx have in circulation?
The max supply of Pulmonx shares is 42.24M.
What is Pulmonx Price to Earnings Ratio (PE Ratio)?
Pulmonx PE Ratio is now.
What was Pulmonx earnings per share over the trailing 12 months (TTM)?
Pulmonx EPS is -1.3 USD over the trailing 12 months.
Which sector does the Pulmonx company belong to?
The Pulmonx sector is Healthcare.
Pulmonx LUNG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}